India's pharma sector is back in the spotlight and investors are closely tracking the next wave of opportunities emerging from the GLP-1 revolution and a strong pipeline of US FDA approvals. As global demand for obesity and diabetes treatments rises, Indian pharmaceutical companies are rapidly expanding their presence in this high-growth segment, including the development of new oral drug variants. In this exclusive market discussion, Gaurav Sharma, Associate VP & Head of Research, Globe Capital decodes why the pharma space is attracting renewed investor interest despite broader market volatility. Strong quarterly earnings, attractive valuations, and increasing global opportunities are creating a favorable setup for select pharmaceutical stocks.
What Women Want: Actors Expose The Truth Behind Freebies & Women Votes In Karnataka!
TMC Implosion? 50 Rebel MLAs Back Ritabrata Banerjee As Rift Deepens Over Abhishek’s Power Hub
Marco Rubio Grilled By Democrats: Why Is US Refusing Sanctions Relief To Reopen Crucial Oil Strait?
U.S. Ambassador Sergio Gor On U.S.-India TRUST Initiative | IIT Delhi Address
AI Fears Crash I.T. Stocks, But Experts See A Massive Buying Opportunity
